

# Wenjie Gong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/940609/publications.pdf>

Version: 2024-02-01

11  
papers

196  
citations

1478505

6  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

204  
citing authors

#	ARTICLE	IF	CITATIONS
1	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. <i>Biomedicines</i> , 2022, 10, 373.	3.2	2
2	Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers. <i>Cancers</i> , 2022, 14, 208.	3.7	5
3	An Endoplasmic Reticulum Specific Pro-amplicifier of Reactive Oxygen Species in Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 11158-11162.	13.8	34
4	An Endoplasmic Reticulum Specific Pro-amplicifier of Reactive Oxygen Species in Cancer Cells. <i>Angewandte Chemie</i> , 2021, 133, 11258-11262.	2.0	5
5	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies. <i>Oncology Reports</i> , 2021, 46, .	2.6	12
6	Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. <i>Cells</i> , 2021, 10, 152.	4.1	2
7	Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD). <i>Blood</i> , 2021, 138, 1810-1810.	1.4	0
8	Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1195-1209.	4.2	27
9	Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. <i>Cytotherapy</i> , 2019, 21, 566-578.	0.7	23
10	Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2019, 145, 1312-1324.	5.1	67
11	Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. <i>Human Gene Therapy</i> , 2018, 29, 1167-1182.	2.7	19